Search hospitals > Florida > Orlando
OrlandoHealth
Claim this profileOrlando, Florida 32806
Global Leader in Breast Cancer
Global Leader in Melanoma
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Heart Failure
190 reported clinical trials
32 medical researchers
Summary
OrlandoHealth is a medical facility located in Orlando, Florida. This center is recognized for care of Breast Cancer, Melanoma, Cancer, Non-Small Cell Lung Cancer, Heart Failure and other specialties. OrlandoHealth is involved with conducting 190 clinical trials across 303 conditions. There are 32 research doctors associated with this hospital, such as Amy Smith, MD, Sajeve S. Thomas, Udayakumar Navaneethan, and Alfredo Voloschin, MD.Area of expertise
1Breast Cancer
Global LeaderHER2
Stage IV
HR
2Melanoma
Global LeaderStage IV
Stage III
BRAF positive
Top PIs
Amy Smith, MDArnold Palmer Hospital for Children7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
54 reported clinical trials
107 drugs studied
Sajeve S. ThomasOrlando Health Cancer Institute7 years of reported clinical research
Expert in Melanoma
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
31 drugs studied
Udayakumar NavaneethanOrlando Health, Inc.5 years of reported clinical research
Studies Ulcerative Colitis
Studies Inflammatory Bowel Disease
5 reported clinical trials
7 drugs studied
Alfredo Voloschin, MDOrlando Health5 years of reported clinical research
Studies Glioblastoma
Studies Recurrence
5 reported clinical trials
16 drugs studied
Clinical Trials running at OrlandoHealth
Ulcerative Colitis
Breast Cancer
Colorectal Cancer
Pancreatic Cancer
Melanoma
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Tumors
Cancer
Skin Cancer
Oral NX-13
for Ulcerative Colitis
This trial is testing a new treatment for people with moderate to severe ulcerative colitis. The goal is to see if this treatment can reduce inflammation and improve symptoms. The study includes a period to monitor the effects over time.
Recruiting0 awards Phase 2
PL-8177
for Ulcerative Colitis
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).
Recruiting0 awards Phase 27 criteria
Hyperbaric Oxygen Therapy
for Ulcerative Colitis
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small molecules, or colectomy. In this larger trial the study aims to confirm the treatment benefits of HBOT for hospitalized UC patients and study the immune-microbe mechanisms underpinning treatment response.
Recruiting0 awards N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at OrlandoHealth?
OrlandoHealth is a medical facility located in Orlando, Florida. This center is recognized for care of Breast Cancer, Melanoma, Cancer, Non-Small Cell Lung Cancer, Heart Failure and other specialties. OrlandoHealth is involved with conducting 190 clinical trials across 303 conditions. There are 32 research doctors associated with this hospital, such as Amy Smith, MD, Sajeve S. Thomas, Udayakumar Navaneethan, and Alfredo Voloschin, MD.